The FDA green lighted Margenza, developed by MacroGenics, Inc. (MGNX) , on December 16, 2020.Margenza (margetuximab-cmkb), in combination with chemotherapy, is indicated for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.The drug comes with boxed warning about left ventricular dysfunction and embryo-fetal toxicity.AstraZeneca and Daiichi Sankyo’s Enhertu, Seagen’s Tukysa and Puma’s Nerlynx are some of the competing therapies for Margenza.MacroGenics expects to make the drug available in the market in March.